Risk-adapted strategies for the treatment of Hodgkin lymphoma |
| |
Authors: | Jesse Keller Kenneth R Carson |
| |
Institution: | 1. Washington University, Division of Oncology, Department of Medicine, St Louis, MO 63110, USA;2. Washington University School of Medicine, Division of Oncology, Department of Internal Medicine, 660 S. Euclid Avenue, Campus Box 8056, St. Louis, MO 63110, USA +1 31 43 62 56 54;3. +1 31 44 54 79 41;4. KCARSON@DOM.wustl.edu;5. Research Service, St. Louis Veterans Affairs Medical Center, 501 N. Grand Blvd Suite 300, St. Louis, MO 63103, USA |
| |
Abstract: | Introduction: Over the past several decades, Hodgkin lymphoma (HL) has become a highly treatable lymphoid malignancy with excellent response rates and long-term disease-free survival. Late-toxicities, however, continue to be an area of significant concern. Recent studies have evaluated novel approaches to limit long-term toxicity without adversely impacting short-term survival. While early or interim PET scan has been correlated with PFS and OS in HL, the modification of therapy based on interim PET (response-adapted therapy) has been evaluated in retrospective and prospective cohorts. This paper will review evidence for the role of response-adapted therapy in HL. Areas covered: Data from completed and ongoing retrospective and prospective cohorts of HL patients were reviewed utilizing pubmed and clinicaltrials.org and pertinent studies culled to compile this review article. Expert opinion: While response-adapted therapy represents a promising area of research which may ultimately become standard-of-care, current data does not unequivocally endorse this approach, which should be used with caution outside of a clinical trial. |
| |
Keywords: | Hodgkin lymphoma interim PET risk stratification |
|
|